A new wave of antibody-targeted anticancer therapies is showing great clinical promise, with the potential to transform cancer treatment. These antibody-drug conjugates (ADCs) are multicomponent ...
Antibody-drug conjugates (ADCs) have emerged as one of the most promising modalities in oncology, offering a way to pair the targeting precision of antibodies with the potency of small-molecule drugs.
Abclone announced on April 7 that the next-generation antibody-drug conjugate (ADC) technology, which it licensed from the Seoul National University Industry-Academic Cooperation Foundation, has ...
Antibiotic resistance is worsening worldwide, and plasmid conjugation is a major way resistance genes spread. A new study in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results